Tatva Chintan Pharma Chem Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Tatva Chintan Pharma Chem Ltd filed with BSE on 21 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Tatva Chintan reported Q1 FY27 operating revenue of INR1,671 million, up 43% year-on-year and 25% sequentially, with EBITDA of INR323 million, up 86% year-on-year. Management highlighted growth across Phase Transfer Catalysts, Pharma & Agro Intermediates, and Structure Directing Agents segments, along with the first commercial-scale semiconductor product batch being qualified by a customer. The Board approved a new greenfield manufacturing facility involving an investment of approximately INR200 crores.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Operating revenue: INR1,671 million (Q1 FY27)
p. 3
“For Q1 FY27, Tatva Chintan reported operating revenue of INR1,671 million, reflecting a 43% year-on-year growth and 25% sequential increase.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
EBITDA: INR323 million (Q1 FY27)
p. 3
“EBITDA stood at INR323 million, representing a 86% growth Y-on-Y and 15% improvement over the previous quarter.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Phase Transfer Catalysts revenue: INR428 million (Q1 FY27)
p. 3
“Phase Transfer Catalysts contributed INR428 million in revenue, a 38% growth quarter-onquarter and 47% increase year-on-year.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Electrolyte Salts revenue: INR63 million (Q1 FY27)
p. 3
“Electrolyte Salts achieved INR63 million in revenue, recording a down 52% sequentially and a growth of 76% Y-o-Y.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Pharma & Agro Intermediates and Specialty Chemicals revenue: INR584 million (Q1 FY27)
p. 3
“Pharma & Agro Intermediates and Specialty Chemicals delivered INR584 million in revenue, 63% growth quarter-on-quarter and a growth of 25% Y-o-Y.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Structure Directing Agents revenue: INR578 million (Q1 FY27)
p. 4
“Structure Directing Agents reported INR578 million in revenue, reflecting a 10% growth quarter-on-quarter and a 47% increase year-on-year.”
Ajesh Pillai, page 4 of the filed PDF · View the filing
Greenfield facility investment: approximately INR200 crores
p. 5
“I'm pleased to share that our Board of Directors has today approved the establishment of a new greenfield manufacturing facility involving an investment of approximately INR200 crores.”
Chintan Shah, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth rate — 25%, 30% growth · FY27
stated firmly by Chintan Shah
p. 11
“We see, yes, so 25%, 30% growth is what we forecasted, and that's what we stick to.”
Chintan Shah, page 11 of the filed PDF · View the filing
EBITDA margin — 20%, 22% · FY27
stated firmly by Chintan Shah
p. 11
“As I always say, so unfortunately, we have lost 1 quarter with a little lesser margin, but I would still stick to 20%, 22% margins in guidance.”
Chintan Shah, page 11 of the filed PDF · View the filing
Electrolyte Salts revenue — INR40 crores to INR60 crores · FY27
stated firmly by Chintan Shah
p. 10
“It will not be up to -- so between INR40 crores to INR60 crores revenue is what we still hold the guidance.”
Chintan Shah, page 10 of the filed PDF · View the filing
Revenue from new pharma molecules — INR70 crores to INR80 crores · FY27
stated firmly by Ajesh Pillai
p. 8
“It should contribute around INR70 crores to INR80 crores of revenue from all these pharma molecules.”
Ajesh Pillai, page 8 of the filed PDF · View the filing
Revenue from pharma molecules at full utilization — INR200 crores
stated as an aspiration by Ajesh Pillai
p. 8
“INR200 crores. In the range of INR200 crores.”
Ajesh Pillai, page 8 of the filed PDF · View the filing
Greenfield facility revenue at peak utilization — INR300 crores
stated as an aspiration by Ajesh Pillai
p. 9
“we would end up having around INR300 crores of revenue at peak utilization.”
Ajesh Pillai, page 9 of the filed PDF · View the filing
Greenfield facility commissioning timeline — 18 to 21 months
stated conditionally by Chintan Shah
p. 11
“So theoretically, we say we want this site to be in place within -- into operations within 21 months. Internally, we are pushing to get it through within 18 months, if possible.”
Chintan Shah, page 11 of the filed PDF · View the filing
Compounded revenue growth — 20% to 25% · next 3 to 4 years
stated as an aspiration by Chintan Shah
p. 15
“we should envisage at least 20% to 25% compounded growth year-on-year basis.”
Chintan Shah, page 15 of the filed PDF · View the filing
Post-tax ROIC — 20%, 22%
stated as an aspiration by Chintan Shah
p. 15
“when we talk of ROIC, we look at about 20%, 22% should be a decent achievement, and that is what we are focusing to in that direction.”
Chintan Shah, page 15 of the filed PDF · View the filing
Hybrid battery customer commercialization — October or November of calendar year 2026
stated conditionally by Chintan Shah
p. 13
“So this should happen from October or November of this year, calendar year '26, whereas the major part of the demand is coming from a couple of customers using these electrolytes into stationary energy storage systems.”
Chintan Shah, page 13 of the filed PDF · View the filing
Full-scale hybrid battery commercialization — late 2027
stated conditionally by Chintan Shah
p. 13
“And then that actual commercialization, so full-scale up commercialization of the hybrid systems is expected to happen somewhere in late 2027.”
Chintan Shah, page 13 of the filed PDF · View the filing
Semiconductor product commercialization — not before Q4 of 2028
stated conditionally by Chintan Shah
p. 11
“Because we don't -- honestly speaking, we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028.”
Chintan Shah, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed growth to widening acceptability of phase-transfer catalysts and said they will continue producing for loyal customers even as more PTC is consumed internally for SDA and Electrolyte Salts.
Answered by Ajesh Pillai
Asked by Shlok Patel: What led to PTC segment growth and can similar numbers be expected going forward?
p. 6
“So as and when the demand of SDA and the Electrolyte Salts & Solutions increase, we will be consuming more PTC into those products, and we will be selling less of PTC into market.”
Ajesh Pillai, page 6 of the filed PDF · View the filing
Management said they see no obstacles as demand from customers and segments is visible.
Answered by Ajesh Pillai
Asked by Pal: What is the biggest execution risk to achieving FY27 guidance?
p. 7
“None of them. We don't foresee any obstacles to this year's guidance because all the demand from the customers and the segments are quite visible.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Management said it is too early to gauge the addressable demand but expects it to be a large potential, requiring multiple plant-scale trials over the next 2 years.
Answered by Chintan Shah
Asked by Raman K.V.: What is the total addressable market for the semiconductor chemical product?
p. 8
“In terms of addressable demand, it is too early right now to gauge, but I'm sure it's going to be a very large potential.”
Chintan Shah, page 8 of the filed PDF · View the filing
Management said Dahej is nearly saturated with only minor debottlenecking possible, and major growth will have to come from the new greenfield site.
Answered by Chintan Shah
Asked by Nirali Gopani: Will additional Dahej capacity be available next year, or only after the new facility?
p. 11
“Dahej, we are nearly saturated. We have consumed all the piece or parcel of land in Dahej.”
Chintan Shah, page 11 of the filed PDF · View the filing
Management said the equipment installed for MONOGLYME was redirected to produce raw material for supercapacitor battery electrolyte after a sharp China-driven price drop made the original plan unattractive.
Answered by Chintan Shah
Asked by Ketan Chheda: What is the status of the MONOGLYME capacity that was previously installed?
p. 16
“The reason why we moved a step back from MONOGLYME is a terrible price drop that happened from China, $4.6, $4.7, $4.8 roughly.”
Chintan Shah, page 16 of the filed PDF · View the filing
Management said there are currently 5 products in the semiconductor pipeline at various stages of development.
Answered by Chintan Shah
Asked by Ketan Chheda: How many products are in the semiconductor chemicals pipeline?
p. 16
“Currently, we have 5 products on pipeline. So, one of this is now produced from the plant scale.”
Chintan Shah, page 16 of the filed PDF · View the filing
Risks flagged
Raw material shortage from Middle East crisis delayed Electrolyte Salts production and revenue recognition
p. 5
“Severe short supply of certain key raw materials due to Middle East crisis led to significant production delays, impacting the revenue recognition for the quarter and the situation is now gradually getting streamlined in terms of its availability.”
Chintan Shah, page 5 of the filed PDF · View the filing
Company has been slow to pass on rising raw material costs, impacting margins
p. 10
“Because actually, honestly speaking, we have not been thorough in terms of passing on the increase in cost. So that is visible on our margins as well.”
Chintan Shah, page 10 of the filed PDF · View the filing
Loss of production due to war-related raw material unavailability
p. 10
“Unfortunately, we lost a couple of months due to unavailability of couple of key raw materials in this space. It just happened because of the war situation, which impacted our productivity.”
Chintan Shah, page 10 of the filed PDF · View the filing
Sharp Chinese price drop undermined MONOGLYME investment economics
p. 16
“In that price range, the product price dropped from there to $2.1. It just happened within 30 days' time frame when they dropped the prices.”
Chintan Shah, page 16 of the filed PDF · View the filing
Flame retardant product commercialization remains unattractive due to polymer industry conditions
p. 16
“Basically, it is directly connected to the polymer industry, and still the situation there is not much reversal in the situation.”
Chintan Shah, page 16 of the filed PDF · View the filing
Semiconductor industry qualification process is slow and rigorous, delaying commercialization
p. 8
“And of course, as you know, any change in semiconductor is extremely difficult. So probably it's not an easy take off.”
Chintan Shah, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.